{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-042770","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.490501+00:00","generated_at":"2026-06-21T14:30:05.061939+00:00","sec_items":["1.01","1.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eterna Therapeutics restructures license with Factor Bioscience, gains right to sublicense three US patents","bullets":["Amendment dated Nov 22, 2022 grants exclusive sublicensing rights to three US patents (10,662,410, 10,829,738, 10,982,229) from Factor to Brooklyn Immunotherapeutics.","Prior Novellus-Factor license terminated; Novellus removed and Factor becomes direct licensor to Brooklyn and NoveCite (25% owned by Eterna).","Brooklyn pays Factor 20% of sublicense fees (first 5-year term) and 30% (potential 2.5-year extension); extension contingent on $100M in sublicense fees.","License term is 5 years, extendable by 2.5 years; Eterna guarantees all payments and obligations of Brooklyn under the amended agreement.","Dr. Matthew Angel, Eterna's interim CEO, is co-founder, President, and CEO of Factor Bioscience's parent; transaction is a related-party deal."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-042770","json":"https://secwatch.observer/filing/0001140361-22-042770.json","markdown":"https://secwatch.observer/filing/0001140361-22-042770.md","text":"https://secwatch.observer/filing/0001140361-22-042770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036122042770/0001140361-22-042770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036122042770/brhc10044587_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T14:30:05.061939+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0be57c4c5dbf36b95c1500d32710ee6885da6b6b","claim":"Ernexa Therapeutics Inc. amended First Amendment with Factor Bioscience Limited (effective 2022-11-22).","evidence_excerpt":"On November 22, 2022 (the “ Amendment Effective Date ”), Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a First Amendment (the “ Amendment ”) to the Exclusive License Agreement, dated as of April 26, 2021 (the “ Original License Agreement ,” and as amended by the Amendment, the “ Amended Factor License Agreement ”), by and among Brooklyn Immunotherapeutics LLC, a wholly owned subsidiary of the Company (“ Brooklyn LLC ”), Novellus Therapeutics Limited, a wholly owned subsidiary of the Company (“ Novellus ”), and Factor Bioscience Limited (“ Factor ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122042770/0001140361-22-042770-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Factor Bioscience Limited"},{"label":"Effective","value":"2022-11-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}